ABIVAX Société Anonyme
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as … Read more
ABIVAX Société Anonyme (AAVXF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.139x
Based on the latest financial reports, ABIVAX Société Anonyme (AAVXF) has a cash flow conversion efficiency ratio of -0.139x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-71.28 Million) by net assets ($511.24 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
ABIVAX Société Anonyme - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how ABIVAX Société Anonyme's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
ABIVAX Société Anonyme Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ABIVAX Société Anonyme ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Suntront Tech
SHE:300259
|
0.009x |
|
Berry Genomics Co Ltd
SHE:000710
|
-0.001x |
|
Custom Truck One Source Inc
NYSE:CTOS
|
0.156x |
|
Beijing Comens New Materials
SHE:300200
|
0.010x |
|
Myson Century, Inc.
TWO:5314
|
0.230x |
|
SEALSQ Corp
NASDAQ:LAES
|
-0.117x |
|
Longkou Union Chemical Co. Ltd. A
SHE:301209
|
0.008x |
|
KCE EL. PCL -NVDR- BA 05
F:NVPA
|
N/A |
Annual Cash Flow Conversion Efficiency for ABIVAX Société Anonyme (2013–2024)
The table below shows the annual cash flow conversion efficiency of ABIVAX Société Anonyme from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $40.58 Million | $-154.07 Million | -3.796x | -666.11% |
| 2023-12-31 | $196.01 Million | $-97.13 Million | -0.496x | +98.58% |
| 2022-12-31 | $1.88 Million | $-65.58 Million | -34.845x | -2096.03% |
| 2021-12-31 | $28.77 Million | $-45.66 Million | -1.587x | +75.14% |
| 2020-12-31 | $4.67 Million | $-29.82 Million | -6.382x | -173.67% |
| 2019-12-31 | $11.78 Million | $-27.47 Million | -2.332x | -453.39% |
| 2018-12-31 | $34.65 Million | $-14.60 Million | -0.421x | -140.30% |
| 2017-12-31 | $48.18 Million | $-8.45 Million | -0.175x | +36.28% |
| 2016-12-31 | $56.72 Million | $-15.61 Million | -0.275x | -32.46% |
| 2015-12-31 | $71.74 Million | $-14.90 Million | -0.208x | -113.32% |
| 2014-12-31 | $33.94 Million | $-3.31 Million | -0.097x | -0.25% |
| 2013-12-31 | $34.02 Million | $-3.31 Million | -0.097x | -- |